ATA11842004A - Impfstoff gegen die alzheimer-krankheit - Google Patents

Impfstoff gegen die alzheimer-krankheit

Info

Publication number
ATA11842004A
ATA11842004A AT0118404A AT11842004A ATA11842004A AT A11842004 A ATA11842004 A AT A11842004A AT 0118404 A AT0118404 A AT 0118404A AT 11842004 A AT11842004 A AT 11842004A AT A11842004 A ATA11842004 A AT A11842004A
Authority
AT
Austria
Prior art keywords
alzheimer disease
vaccine against
vaccine
alzheimer
disease
Prior art date
Application number
AT0118404A
Other languages
English (en)
Other versions
AT413946B (de
Original Assignee
Mattner Frank Dr
Schmidt Walter Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mattner Frank Dr, Schmidt Walter Dr filed Critical Mattner Frank Dr
Priority to AT0118404A priority Critical patent/AT413946B/de
Priority to TW094120197A priority patent/TWI353848B/zh
Priority to EP05769807A priority patent/EP1765390A2/de
Priority to CA002573424A priority patent/CA2573424A1/en
Priority to CNA2005800306410A priority patent/CN101043901A/zh
Priority to KR1020077002209A priority patent/KR101228409B1/ko
Priority to US11/630,679 priority patent/US8022180B2/en
Priority to CN2012105573960A priority patent/CN103263664A/zh
Priority to PCT/EP2005/053225 priority patent/WO2006005707A2/en
Priority to JP2007520814A priority patent/JP5179866B2/ja
Priority to AU2005261688A priority patent/AU2005261688B2/en
Publication of ATA11842004A publication Critical patent/ATA11842004A/de
Application granted granted Critical
Publication of AT413946B publication Critical patent/AT413946B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0118404A 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit AT413946B (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit
TW094120197A TWI353848B (en) 2004-07-13 2005-06-17 Mimotope peptide,composition,and immunogenic compo
CA002573424A CA2573424A1 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
CNA2005800306410A CN101043901A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法
EP05769807A EP1765390A2 (de) 2004-07-13 2005-07-06 Verfahren zur vorbeugung und behandlung der alzheimer-krankheit
KR1020077002209A KR101228409B1 (ko) 2004-07-13 2005-07-06 알츠하이머 질환의 예방 및 치료 방법
US11/630,679 US8022180B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer's disease
CN2012105573960A CN103263664A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法
PCT/EP2005/053225 WO2006005707A2 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
JP2007520814A JP5179866B2 (ja) 2004-07-13 2005-07-06 アルツハイマー病の予防および治療方法
AU2005261688A AU2005261688B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer´s disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Publications (2)

Publication Number Publication Date
ATA11842004A true ATA11842004A (de) 2005-11-15
AT413946B AT413946B (de) 2006-07-15

Family

ID=35406000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Country Status (10)

Country Link
US (1) US8022180B2 (de)
EP (1) EP1765390A2 (de)
JP (1) JP5179866B2 (de)
KR (1) KR101228409B1 (de)
CN (2) CN101043901A (de)
AT (1) AT413946B (de)
AU (1) AU2005261688B2 (de)
CA (1) CA2573424A1 (de)
TW (1) TWI353848B (de)
WO (1) WO2006005707A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
KR100820164B1 (ko) 2007-03-31 2008-04-08 한국전기연구원 피부질환 치료용 레이저 장치
KR100815483B1 (ko) 2007-05-09 2008-03-20 한국전기연구원 비등방성 레이저 결정을 이용한 다이오드 펌핑된 레이저장치
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009054537A1 (ja) * 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
CA2723995A1 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
WO2011106732A1 (en) 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
KR101849975B1 (ko) * 2011-01-17 2018-05-31 삼성전자주식회사 음극, 음극 활물질, 음극의 제조방법 및 이를 채용한 리튬 전지
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
WO2013099806A1 (ja) * 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
EP2659908A1 (de) * 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
EP3027205A4 (de) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Impfstoffformulierungen zur induzierung einer th2-immunantwort
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
DK3137094T3 (da) 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3911389B1 (de) 2019-01-14 2023-03-01 Philip Morris Products, S.A. Trockenpulverinhalatorvorrichtung
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
IL149472A0 (en) * 1999-12-30 2002-11-10 Bristol Myers Squibb Co Nucleotide sequences and polypeptides encoded by the sequences that are essential for bacterial viability and methods for detecting and utilizing the same
DE60217107T2 (de) * 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
EA007452B1 (ru) 2002-04-12 2006-10-27 Пи Джи Рисерч Фаундейшн, Инк. Многоколоночный генератор с инверсией избирательности для производства сверхчистых радионуклидов
JP2004016282A (ja) 2002-06-12 2004-01-22 Olympus Corp 内視鏡用画像処理装置
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit

Also Published As

Publication number Publication date
WO2006005707A2 (en) 2006-01-19
US8022180B2 (en) 2011-09-20
US20090004210A1 (en) 2009-01-01
AT413946B (de) 2006-07-15
EP1765390A2 (de) 2007-03-28
CN103263664A (zh) 2013-08-28
KR101228409B1 (ko) 2013-01-31
JP2008506666A (ja) 2008-03-06
TW200602071A (en) 2006-01-16
CN101043901A (zh) 2007-09-26
KR20070032033A (ko) 2007-03-20
WO2006005707A3 (en) 2006-08-17
TWI353848B (en) 2011-12-11
CA2573424A1 (en) 2006-01-19
AU2005261688A1 (en) 2006-01-19
JP5179866B2 (ja) 2013-04-10
AU2005261688B2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
DK1968631T3 (da) Vaccine
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
NO20054608D0 (no) Influensavirusvaksine
DK1957528T3 (da) Nukleotid-vaccine
ATE515515T1 (de) Immunglobuline gegen menschlisches osm
DE602005010597D1 (de) Bildaufzeichnungsverfahren
ATE432082T1 (de) Impfstoff gegen periodontale krankheit
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
DK1957073T3 (da) Lægemiddel
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
IS8325A (is) Bóluefni
EP1948782A4 (de) Impfstoffadjuvantien
DE602005003524D1 (de) Biegevorrichtung
DK1660123T3 (da) Rotavirusvaccine
DE602005024139D1 (de) Die anzeigevorrichtung
DK1877549T3 (da) HIV-vaccine
DE602006014799D1 (de) Heilmittel gegen sensorische erkrankungen
ES1058102Y (es) Lentilla terapeutica.
ES2365717T5 (es) Vacunacion meningococica conjugada.
DK1960510T3 (da) Ammoniakspecifik 5'-xmp-aminasemutant
FI6726U1 (fi) Hieromalaite
DE602005000531D1 (de) Formgesenk
ITCR20050007U1 (it) Piegaprofili "stefiglass"

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20151115